Onconova Therapeutics, Inc. ONTX shares are trading higher after the company reported preliminary data from a Phase 1/2 a trial of rigosertib plus immune checkpoint inhibitor nivolumab, which are being presented at the 3rd Annual RAS Targeted Drug Development Summit.
Onconova Therapeutics is currently up 32.3% to a price of $6.48. The stock's volume is currently 71.99 million, which is roughly 28840.0% of its recent 30-day volume average of 249.62 thousand.
The 50-day moving average price of Onconova Therapeutics's stock was $5.1 when this article was published. The stock reached a high of $10.84 and a low of $0.24 in the past 52 weeks.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
